Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

It's been nearly five years since Moderna (NASDAQ: MRNA) emerged as a biotech industry disruptor, with its COVID-19 vaccine ...

Moderna (NASDAQ:MRNA – Get Free Report) had its price objective lowered by analysts at JPMorgan Chase & Co. from $40.00 to ...

Shares of Moderna, Inc. (NASDAQ:MRNA – Get Free Report) have been assigned an average rating of “Hold” from the twenty-four ...

CompanyOverview|NASDAQ:MRNA] The CEO of Moderna Inc. (NASDAQ: MRNA) just purchased $5 million of stock in the open market.

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...

Our analysis of options history for Moderna (NASDAQ:MRNA) revealed 10 unusual trades. Delving into the details, we found 40% of traders were bullish, while 50% showed bearish tendencies.

Ben McPoland considers a pair of investments that are performing awfully in his ISA portfolio so far this year. What's gone ...

Citigroup assumed coverage on shares of Moderna (NASDAQ:MRNA – Free Report) in a research report report published on Thursday ...

Let’s dig into the relative performance of Vertex Pharmaceuticals (NASDAQ:VRTX) and its peers as we unravel the now-completed Q4 therapeutics earnings season. Over the next few years, therapeutic ...

It's been nearly five years since Moderna (NASDAQ: MRNA) emerged as a biotech industry disruptor, with its COVID-19 vaccine playing a landmark role in tackling the global pandemic in late 2020.

The CEO of Moderna Inc. (NASDAQ: MRNA) just purchased $5 million of stock in the open market. This is very significant since most of the insider trades have been sales for the past year.